NPS R-568 halts or reverses osteitis fibrosa in uremic rats

Kidney International

Volumn 53, Issue 2, 1998, Pages 448-453

  Wada, Michihito ^b   Ishii, Hiromi ^b   Furuya, Yoshihiro ^b   Fox, John ^b   Nemeth, Edward F ^b   Nagano, Nobuo ^a  

^a KIRIN BREWERY CO LTD   (Japan)

^b NONE

Author keywords

Ca2+ receptor; Calcimimetics; Osteitis fibrosa; Parathyroid hormone; Renal osteodystrophy; Secondary hyperparathyroidism

Indexed keywords

CALCIUM CHANNEL STIMULATING AGENT; N (3 [2 CHLOROPHENYL]PROPYL) ALPHA METHYL 3 METHOXYBENZYLAMINE; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PARATHYROID HORMONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MINERAL; CONTROLLED STUDY; DOSE RESPONSE; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEITIS FIBROSA; PARATHYROID HORMONE BLOOD LEVEL; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; RAT; SECONDARY HYPERPARATHYROIDISM; UREMIA;

EID: 0031885412     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00782.x     Document Type: Article

References (34)

1. MALLUCHE H, FAUGERE M-C: Renal bone disease 1990: An unmet challenge for the nephrologist. Kidney Int 38:193-211, 1990
2. LLACH F, BOVER J: Renal osteodystrophy, in The Kidney (vol II), edited by BRENNER BM, Philadelphia, W.B. Saunders Company, 1996, pp 2187-2273
3. SLATOPOLSKY E, DELMEZ JA: Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 23:229-236, 1994
4. SHERRARD DJ, HERCZ G, PEI Y, MALONEY NA, GREENWOOD C, MANUEL A, SAIPHOO C, FENTON SS, SEGRE GV: The spectrum of bone disease in end-stage renal failure: An evolving disorder. Kidney Int 43:436-442, 1993
5. ANTONSEN JE, SHERRARD DJ: Renal osteodystrophy: Past and present. Semin Dial 9:296-302, 1996
6. VOIGTS A, FELSENFELD AJ, ANDRESS D, LLACH F: Parathyroid hormone and bone histology: Response to hypocalcemia in osteitis fibrosa. Kidney Int 25:445-452, 1984
7. WEINSTEIN RS: Decreased mineralization in hemodialysis patients after subtotal parathyroidectomy. Calcif Tissue Int 34:16-20, 1982
8. CHARHON SA, BERLAND YF, OLMER MJ, DELAWARI E, TRAEGER J, MEUNIER PJ: Effects of parathyroidectomy on bone formation and mineralization in hemodialyzed patients. Kidney Int 27:426-435, 1985
9. KITAZAWA R, IMAI Y, FUKASE M, FUJITA T: Effects of continuous infusion of parathyroid hormone and parathyroid hormone-related peptide on rat bone in vivo: Comparative study by histomorphometry. Bone Miner 12:157-166, 1991
10. 3 in the management of renal osteodystrophy. Kidney Int 19:409-418, 1980
11. VOIGTS AL, FELSENFELD AJ, LLACH F: The effects of calciferol and its metabolites on patients with chronic renal failure. Arch Inter Med 143:1205-1211, 1983
12. 2+-sensing receptor from bovine parathyroid. Nature 366:575-580, 1993
13. 2+ receptor-dependent regulation of cellular functions. NIPS 10:1-5, 1995
14. 2+ receptor: A novel therapeutic target for the treatment of hyperparathyroidism. Pediatr Nephrol 10:275-279, 1996
15. NEMETH EF: Calcium receptors as novel drug targets, in Principles of Bone Biology edited by BILEZIKIAN JP, RAISZ LG, RODAN GA, San Diego, Academic Press, 1996, pp 1019-1035
16. FOX J, HADFIELD S, PETTY BA, NEMETH EF: A first generation calcimimetic compound (NPS R-568) that acts on the parathyroid cell calcium receptor: A novel therapeutic approach for hyperparathyroidism. J Bone Miner Res 8(Suppl 1):S181, 1993
17. NAGANO N, FURUYA Y, ISHII H, WADA M: Pharmacology of the calcium-receptor agonist KRN568 in normal rats. (abstract) Jpn J Nephrol 38(Suppl):50, 1996
18. HEATH H, III, SANGUINETTI EL, OGLESBY S, MARRIOTT TB: Inhibition of human parathyroid hormone secretion in vivo by NPS R-568, a calcimimetic drug that targets the parathyroid cell-surface calcium receptor. Bone 16(Suppl 1):85S, 1995
19. SILVERBERG SJ, THYS-JACOBS S, LOCKER FG, SANGUINETTI EL, MARRIOTT TB, BILEZIKIAN JP: The effect of the calcimimetic drug NPS R-568 on parathyroid hormone secretion in primary hyperparathyroidism. J Bone Miner Res 11(Suppl 1):S116, 1996
20. FOX J, MILLER MA, CONKLIN RL, LOWE SH, PETTY BA, NEMETH EF: The calcimimetic NPS R-568 prevents the development of secondary hyperparathyroidism and elevated bone formation in rats with mild chronic renal insufficiency. J Bone Miner Res 10(Suppl 1):S191, 1995
21. MANAKA RC, MALLUCHE HH: A program package for quantitative analysis of histologie structure and remodeling dynamics of bone. Comput Programs Biomed 13:191-202, 1981
22. MALLUCHE HH, SHERMAN D, MEYER W, MASSRY SG: A new semiautomatic method for quantitative static and dynamic bone histology. Calcif Tissue Int 34:439-448, 1982
23. PARFITT AM, DREZNER MK, GLORIEUX FH, KANIS JA, MALLUCHE H, MEUNIER PJ, OTT SM, RECKER RR: Bone histomorphometry: Standardization of normenclature, symbols, and units. J Bone Miner Res 2:595-610, 1987
24. EINHORN TA: Bone strength: The bottom line. Calcif Tissue Int 51:333-339, 1992
25. TURNER CH, BURR DB: Basic biomechanical measurements of bone: A tutorial. Bone 14:595-608, 1993
26. SATO M, MCCLINTOCK C, KIM J, TURNER CH, BRYANT HU, MAGEE D, SLEMENDA CW: Dual-energy x-ray absorptiometry of raloxifene effects on the lumber vertebrae and femora of ovariectomized rats. J Bone Miner Res 9:715-724, 1994
27. FOURNIER A, HARDY YVERNEAU PPH, SAID S, HAMDINI N, MOHY ELDIN H, MOHAGEB S, OPRISIU R, MARIE A, COHEN SOLAL ME, MORINIÈRE P: Adynamic bone disease in patients with uremia. Curr Opin Nephrol Hypertens 3:396-410, 1994
28. FERRETTI JL: Perspectives of pQCT technology associated to biomechanical studies in skeletal research employing rat models. Bone 17:353S-364S, 1995
29. CHRISTIANSEN P, STEINICHE T, BROCKSTEDT H, MOSEKILDE L, HESSOV I, MELSEN F: Primary hyperparathyroidism: Iliac crest cortical thickness, structure, and remodeling evaluated by histomorphometric methods. Bone 14:755-762, 1993
30. BROCKSTEDT H, CHRISTIANSEN P, MOSEKILDE L, MELSEN F: Reconstruction of cortical bone remodeling in untreated primary hyperparathyroidism and following surgery. Bone 16:109-117, 1995
31. JABLONSKI G, KLEM KH, ATTRAMADAL A, DAHL E, RØNNINGEN H, GAUTVIK KM, HAUG E, GORDELADZE JO: Surgically induced uremia in rats I: Effect on bone strength and metabolism. Biosci Rep 13:275-287, 1993
32. SMITH SR, BURSHELL A, LINDBERG J, BOBER M, DAVIES M: Preservation of mechanical properties in secondary hyperparathyroidism: Ulnar stiffness and bone mineral density in end stage renal disease. (abstract) J Bone Miner Res 9:S426, 1994
33. HERCZ G, SHERRARD DJ, CHAN W, PEI Y: Aplastic osteodystrophy: Follow-up after 5 years. (abstract) J Am Soc Nephrol 5:851, 1994
34. PEI Y, HERCZ G, GREENWOOD C, SEGRE G, MANUEL A, SAIPHOO C, FENTON S, SHERRARD D: Risk factors for renal osteodystrophy: A multivariant analysis. J Bone Miner Res 10:149-156, 1995